We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Weight loss drug Ozempic may now smash these FTSE 100 stocks

The new breed of weight loss treatments may be a big win for the pharmaceutical sector but other FTSE 100 stocks may rue the day.

Female Doctor In White Coat Having Meeting With Woman Patient In Office

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Even major FTSE 100 stocks aren’t immune to Black Swan events and one of them could be heading their way in the shape of GLP-1 weight loss drugs like Ozempic and Wegovy.

These are the two best known prescription medications for people living with obesity. Their early success has put a rocket under the shares of Danish pharmaceutical company Novo Nordisk, now Europe’s biggest company. Other sectors won’t come out of this so well.

Should you buy Rolls Royce shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

GLP-1 drugs were developed to treat type II diabetes, by helping users reduce blood sugar levels. They suppress appetite by telling the brain you’re full. They also slow digestion, so food takes longer to leave the body. It’s a huge step forward.

Unforeseen consequences

However, it may be a huge step backwards for FTSE 100 companies selling addictive products like sugar, alcohol and tobacco, which could experience a sharp drop in demand among their most avid users.

If I was the CEO of British American Tobacco, Imperial Brands and spirits maker Diageo, I’d be worried. We all know how hard it is to quit smoking. Around 30% of smokers try every year, but few succeed at the first attempt. 

Giving up drinking isn’t easy either. Dry January has made some inroads and younger drinkers are boozing less. There are an estimated 600,000 dependent drinkers in the UK, but less than one in five receive treatment. Now those who want to kick or cut back have another weapon in their armoury. Diageo’s biggest market is the US. Ozempic et al will be huge over there.

There could be a snowball effect too. As more people stop drinking, it will become easier for politicians to crack down on those who do. I’m keen to add Diageo to my portfolio, taking advantage of a 15% drop in its share price over the last year. Now there’s a new threat I hadn’t considered.

Could be a game changer

I did buy consumer goods giant Unilever recently, as its shares looked nicely priced. However, as well as soap and shampoo, Unilever owns Ben & Jerry’s, and we all know how addictive that is. Plus it owns Hellmann’s, Knorr, Magnum and Wall’s.

Associated British Foods could also be at risk. Its grocery brands include Allinson’s, Allied Bakeries, Blue Dragon, Patak’s, Kingsmill, Jordans, Mazola and Silver Spoon. ABF’s sugar business has the capacity to produce some 4.5m tonnes of sugar annually. Will the world be eating as much of it in future? At least ABF has Primark. All those newly slim shoppers will need a new wardrobe.

What about Tesco, Sainsbury’s, Ocado, Marks & Spencer Group? For that matter, what about The Restaurant Group? Greggs?

These are early days. Not everybody will be taking Ozempic. But with the Health Survey for England 2021 estimating 25.9% of adults in England are obese and a further 37.9% are overweight, many will be tempted. It’s something investors in FTSE 100 food, alcohol and tobacco stocks didn’t have to consider a few months ago.

Fortunately, there are plenty of other Footsie stocks that won’t be affected, whatever happens. There are plenty that I’m bullish on right now, too many to mention them all here of course. Make no mistake, I still believe buying shares in quality companies is the best route to wealth generation available to us all!

Harvey Jones has positions in Unilever Plc. The Motley Fool UK has recommended Associated British Foods Plc, British American Tobacco P.l.c., Diageo Plc, Imperial Brands Plc, J Sainsbury Plc, Novo Nordisk, Ocado Group Plc, Tesco Plc, and Unilever Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Happy parents playing with little kids riding in box
Dividend Shares

How much is needed in a Stocks and Shares ISA to target a £1,370 monthly passive income?

Want to retire early and live off passive income? James Beard explains how someone could aim to do this with…

Read more »

Rolls-Royce Hydrogen Test Rig at Loughborough University
Investing Articles

Here’s how nuclear energy could reignite a fire under Rolls-Royce shares

Mark Hartley weighs up the long-term dividend potential of Rolls-Royce shares and how its SMR division could help drive growth.

Read more »

A rear view of a female in a bright yellow coat walking along the historic street known as The Shambles in York, UK which is a popular tourist destination in this Yorkshire city.
Investing Articles

Here’s how much is needed in an ISA to earn £46,918 of passive income a year

Mark Hartley takes a look at the kind of investment power needed to bring in enough passive income for a…

Read more »

Investing Articles

3 beaten-down FTSE 100 shares to consider buying and holding for a decade

Harvey Jones says the real rewards of investing in FTSE 100 shares come over the long term. He thinks these…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

At 237.8%, the stock market total value-to-GDP ratio is way too high. Here’s what I’m doing.

With the stock market looking more overvalued than at any other time in history, Mark Hartley carefully considers how UK…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

Greggs shares may look cheap – but they expose a classic investing dilemma!

Greggs shares seem to be going nowhere fast. This shareholder reckons it could be an example of a classic stock…

Read more »

Investing Articles

Here’s how long it could take to go from zero to a £1m Stocks and Shares ISA

Ben McPoland sees this dividend-paying ETF as a solid contender for inclusion in a diversified Stocks and Shares ISA today.

Read more »

Business manager working at a pub doing the accountancy and some paperwork using a laptop computer
Investing Articles

Down 33%, is there a once-in-a-decade chance to buy this quality FTSE 100 stock?

This FTSE 100 stock's been written off as a loser in the age of artificial intelligence. But what if the…

Read more »